Program  Highlights

Kenes Multisite 2 Sites > ICLE 2025 > Program  Highlights

Program  Highlights

ICLE 2025 will showcase the most recent scientific advancements in lymphocyte engineering. It will also explore how these new findings can be used in the real world of medicine.

Take a look at the highlights below to learn more about what will be covered.

UPDATE ON THE
APPROVED THERAPIES

First look at post marketing
real world data on the
approved CAR-T cell therapies.

CURRENTLY ONGOING
CLINICAL TRIALS

Discover clinical data
from company, as well as
investigator initiated trials.

NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES

Potential synergy b/n engineered lymphocytes & other treatment modalities will be demonstrated.

SUPERPOWERED
LYMPHOCYTES

Learn more about engineering of lymphocytes for the co-expression of varied immune effectors in addition to the transgenic receptor.

NON-VIRAL
CAR/TCR ENGINEERING

Recent advancement in non viral lymphocyte engineering by means of electroporation or nanocarriers encapsulating mRNA or DNA.

UNIVERSAL DONOR CELLS &
ADVANCED TCR ENGINEERING

A deeper look at
allogeneic therapies,
including those applying
genome editing technologies.

BEYOND
ALPHA-BETA T CELLS

Discuss the engineering of alternative leukocytes including Gamma-Delta T cells, iNKT cells, NK cells, B cells and macrophages.

IN VIVO
T CELL ENGINEERING

Advancement in the scalable engineering of lymphocytes in vivo, reducing costs, timelines and pre conditioning requirements.

TARGETING
NON-MALIGNANT DISEASES

Targeting of non-malignant diseases, including infectious diseases, auto-immune diseases, cardiovascular diseases, genetic disorders and more.

EXPLORE THE FULL SCIENTIFIC PROGRAM